SARMs and the regulatory reality: research-only labels do not change legal posture

FDA posture, in plain language

The FDA has flagged SARM bulk substances within its compounding-substance posture and has not approved any SARM as a finished drug product for body-composition or anti-aging use . These compounds were developed as investigational tissue-selective androgen receptor modulators in pharmaceutical pipelines. The hepatotoxicity and HPG-axis suppression signals that show up in case reports are documented separately in the published case literature .

The 'research only' or 'not for human consumption' label is not a regulatory category. It does not change FDA jurisdiction, it does not authorize sale for human use, and it does not protect a vendor or buyer if the product is sold or used as an unapproved drug.

WADA prohibition is unconditional

Selective androgen receptor modulators are listed under section S1.2 of the World Anti-Doping Agency prohibited list and are prohibited at all times, in and out of competition . This includes ostarine, ligandrol, andarine, and any chemical analog. Many SARM-adjacent metabolic modulators (cardarine / GW-501516, stenabolic / SR9009) sit under section S4.5 and are also prohibited.

USADA and other national anti-doping organizations regularly publish sanction notices for athletes testing positive for SARM metabolites, often from contaminated supplements rather than intentional use .

State-level scheduling, in the United States

LGD-4033 (ligandrol) and RAD-140 (testolone) have been added to state-level controlled substances schedules in several US states, with placement varying. The federal Controlled Substances Act has not scheduled SARMs as a class as of this writing, but state schedules do create criminal exposure that is independent of federal law.

Evidence and risk profile

• No SARM has completed a phase 3 program for body-composition use. Ostarine (MK-2866) has the largest published trial footprint, primarily in cancer cachexia and stress urinary incontinence indications, both abandoned commercially.
• Hepatotoxicity and hepatic dysfunction case reports are documented in the published case-series literature for ligandrol and RAD-140 .
• Suppression of the hypothalamic-pituitary-gonadal axis has been observed in human studies of ostarine and is consistent with class pharmacology.
• Cardiovascular signal (lipid changes, particularly HDL suppression) is dose-dependent in the published human pharmacology data.